TNF and infection: Psoriasis management guidelines from the American Academy of Dermatology (AAD) stress the need for biologic treatments, including IL-17, IL-23, and TNF inhibitors, tailored to disease severity and patient comorbidities, while also addressing the potential side effects like increased risk of infection [3].